Skip to main content

Search Articles

Found 3,094 articles

  • About Vectura

    About Vectura

    • 24 Apr 2024
    • Editor

    Vectura is a specialist inhalation contract development and manufacturing organization (CDMO) that provides inhaled drug development solutions to help customers bring their medicines to patients.

  • Voydeya approved in the EU as add-on treatment to

    Voydeya approved in the EU as add-on treatment to ravulizumab or eculizumab for adults with the rare disease PNH who have residual haemolytic anaemia

    • 24 Apr 2024
    • Editor

    Voydeya (danicopan) has been approved in the European Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia.

  • Vertex and TreeFrog Therapeutics Announce Licensin

    Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex’s Cell Therapies for Type 1 Diabetes

    • 24 Apr 2024
    • Editor

    Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog’s proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex’s cell therapies for type 1 diabetes (T1D).

  • About Mundipharma

    About Mundipharma

    • 23 Apr 2024
    • Editor

    Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America and the Middle East.

  • European Commission Approves Pfizer’s EMBLAVEO® fo

    European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options

    • 23 Apr 2024
    • Editor

    Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis.

  • Rilzabrutinib LUNA 3 phase 3 study met primary end

    Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

    • 23 Apr 2024
    • Editor

    Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia (ITP).

  • Bristol Myers Squibb and Cellares Announce a $380M

    Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster

    • 23 Apr 2024
    • Editor

    Bristol Myers Squibb (NYSE: BMY) and Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, today announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies in a transaction valued up to $380M in upfront and milestone payments.

  • Lilly Acquires New Injectable Medicine Manufacturi

    Lilly Acquires New Injectable Medicine Manufacturing Facility from Nexus Pharmaceuticals

    • 23 Apr 2024
    • Editor

    Eli Lilly and Company (NYSE: LLY) and Nexus Pharmaceuticals, LLC today announced a definitive agreement for Lilly to acquire a manufacturing facility from Nexus, a leading sterile manufacturer in the pharmaceutical industry.

  • Employer Branded Career Hubs

    Employer Branded Career Hubs

    • 22 Apr 2024
    • Nola Cadman

    Visit one of the Employer Branded Career hubs to find out more about what it is like to work at the organisation, the company ethos, and other valuable career information.

  • Emerging Trends in Clinical Data Management and Th

    Emerging Trends in Clinical Data Management and Their Impact on Hiring Needs

    • 22 Apr 2024
    • Lucy Walters

    In the rapidly evolving landscape of clinical trials, the role of data manager stands ever more critical at the confluence of innovation, technology, and regulatory compliance.

  • Amarna Therapeutics announces appointment of Aurel

    Amarna Therapeutics announces appointment of Aurelia Caparrós as new Chief Business Officer

    • 22 Apr 2024
    • Editor

    Amarna Therapeutics, a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Type 1 Diabetes Mellitus, today announces the appointment of Aurelia Caparrós as the Company’s new Chief Business Officer (CBO), effective 1st of April 2024.

  • Polaroid Therapeutics Announces Strategic Hire: Ma

    Polaroid Therapeutics Announces Strategic Hire: Markus Rothmaier Takes Helm of Research and Development

    • 19 Apr 2024
    • Editor

    Polaroid Therapeutics, a Swiss-based biotech start-up, today announces the appointment of Markus Rothmaier as its inaugural Head of Research and Development (R&D).

  • Regulatory Affairs Employers in Europe

    Regulatory Affairs Employers in Europe

    • 17 Apr 2024
    • Editor

    An up-to-date list of employers in Europe, hiring for regulatory affairs positions right now.

  • Data Management Employers in Europe

    Data Management Employers in Europe

    • 17 Apr 2024
    • Editor

    An up-to-date list of employers in Europe, hiring for data management / stats positions right now.

  • Servier Executive Committee appointments

    Servier Executive Committee appointments

    • 17 Apr 2024
    • Editor

    Previously Head of the Group Transformation & Programs Office, Charlotte Marmousez-Tartar is promoted to the position of Executive Vice President, Corporate Strategy and Transformation. She joined the Executive Committee on February 1, 2024, succeeding Siham Imani.

  • Sciensus appoints Hugues Hervouet as its Chi

    Sciensus appoints Hugues Hervouet as its Chief Technology Officer

    • 17 Apr 2024
    • Editor

    Hugues Hervouet has been appointed as Sciensus’ Chief Technology Officer. Hugues joins Sciensus having recently served as Senior Vice President and Chief Information Officer at Shutterstock, a leading global technology provider offering high-quality digital content, tools and services.

  • Martin Meeson, former CEO of Fujifilm Diosynth Bio

    Martin Meeson, former CEO of Fujifilm Diosynth Biotechnologies succeeds Sylke Hassel following the integration of Novasep

    • 17 Apr 2024
    • Editor

    Axplora, a leading partner to Pharma companies and Biotechs for complex APIs, is pleased to announce the appointment of Martin Meeson as its new Chief Executive Officer (CEO).

  • New 48-week frexalimab phase 2 data support potent

    New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

    • 17 Apr 2024
    • Editor

    Sanofi’s CD40L antibody, frexalimab, demonstrated sustained reduction of disease activity and favorable tolerability after nearly one year in participants with relapsing multiple sclerosis.

  • Takeda Recognized with 2024 ISPE Facility of the Y

    Takeda Recognized with 2024 ISPE Facility of the Year Awards in Category Operations

    • 17 Apr 2024
    • Editor

    Takeda (TSE:4502/NYSE:TAK) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in the category Operations with the 2024 Facility of the Year Awards (FOYA).

  • Lantern Pharma is harnessing the power of AI and M

    Lantern Pharma is harnessing the power of AI and Machine Learning to Fight Cancer

    • 16 Apr 2024
    • Editor

    This year, the United States expects to tally more than two million new cancer diagnoses— a first-ever prediction— and more than 611,000 cancer-related deaths.